CN1554395A - Chinese medicinal composition for treating rheumatoid arthritis - Google Patents
Chinese medicinal composition for treating rheumatoid arthritis Download PDFInfo
- Publication number
- CN1554395A CN1554395A CNA2003101146426A CN200310114642A CN1554395A CN 1554395 A CN1554395 A CN 1554395A CN A2003101146426 A CNA2003101146426 A CN A2003101146426A CN 200310114642 A CN200310114642 A CN 200310114642A CN 1554395 A CN1554395 A CN 1554395A
- Authority
- CN
- China
- Prior art keywords
- medicine
- group
- present
- radix
- dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The Chinese medicine composition is prepared with eight kinds of Chinese medicinal materials including honeysuckle, orietvine stem, white peony root, paniculate bolbostemma rhizome, dry ginger, etc. as well as medicinal supplementary material. The Chinese medicine composition has the advantages of high curative effect on rheumatoid arthritis, no toxic side effect, low cost, convenient taking and no recurrence.
Description
(1) technical field under
The invention belongs to a kind of medicine for the treatment of rheumatoid disease, particularly a kind of pure Chinese medicinal preparation for the treatment of rheumatoid disease.
(2) background technology
Rheumatoid arthritis is that a symmetry polyarthritis is heterogeneity, the systemic disease of main clinical manifestation, and the cause of disease it be unclear that.At present think that the generation of this disease is relevant with factors such as infection, immunologic derangement, hormone and environment more.Primary disease is a kind of chronic progressive external, affecting conditions, and the state of an illness developed gradually and increased the weight of if do not give suitable treatment active stage.Cause deformity in various degree such as ankylosis, deformity, afunction at last.Modern medicine is in treatment at present, medicine accounts for space of top prominence, mainly comprise nonsteroidal antiinflammatory drug, slowly act on antirheumatic, immunosuppressant, glucocorticoids etc., no matter the treatment pattern is pyramid or pyramid pattern, sawtooth pattern, top bar or the get out of a predicament or an embarrassing situation pattern or the drug combination of improvement, does not all have the curative effect of determining.And these medicines are taken the side effect that can occur in various degree for a long time in a large number, and the patient who has can not tolerate midway and stop using, and these drug prices are comparatively expensive, cause enormous economic loss to patient.
(3) summary of the invention
The object of the present invention is to provide a kind of therapeutic effect remarkable, have no side effect, cheap, the medicine of the pure Chinese medicinal preparation that does not recur after the treatment.
The present invention realizes by following measure:
Chinese medicine composition of the present invention is to be made by following materials of weight proportions and pharmaceutically acceptable auxiliaries,
Flos Lonicerae 300-400g Caulis Sinomenii 230-300g Radix Paeoniae Alba 200-300g
Rhizoma Bolbostematis 150-200g Rhizoma Zingiberis 30-80g Caulis Sargentodoxae 200-300g
Radix Isatidis 200-300g Radix Cyathulae 200-300g
Chinese medicine composition of the present invention, the more preferably scope of above-mentioned raw materials be,
Flos Lonicerae 340-380g Caulis Sinomenii 260-300g Radix Paeoniae Alba 220-280g
Rhizoma Bolbostematis 160-200g Rhizoma Zingiberis 40-70g Caulis Sargentodoxae 220-280g
Radix Isatidis 220-280g Radix Cyathulae 220-280g
Medicine of the present invention can be made capsule formulation, tablet, granule and other dosage form.
The side of A medicine of the present invention separates and preparation technology
1. ultimate principle
The present invention treats rheumatoid arthritis and makes laws with heat clearing away, and thermogravimetric is in wet person, heat-clearing and toxic substances removing; Weight in wet base is in hot person, and clearing away heat-damp and promoting diuresis detoxifies; Have rheumatism person concurrently, assistant is with the damp eliminating of dispeling the wind.
2. the side separates
2.1 monarch drug: Flos Lonicerae
Flos Lonicerae: sweet cold, heat-clearing and toxic substances removing, wind and heat dispersing, carry in " book on Chinese herbal medicine justice " its " be good at removing toxic substances, thus control carbuncle, toxic swelling, the skin ulcer tinea, Fructus Myricae rubrae, all poison of rheumatism really are key medicine." " Chongqing hall random notes " say its " clear network in wind-fire damp and hot ".Because the sweet cold clear virtue of Flos Lonicerae, property a surname is partially loose, the treatment pyretic arthralgia, and the intrinsic heat poison that both can let out internal organs is evil, but the hot and suffocating heat-clearing and toxic substances removing of removing summer-heat meridians and not injuring one's stomach again, fragrance reaches thoroughly and does not accumulate heresy, applicable to pyretic arthralgia.
2.2 ministerial drug: Rhizoma Bolbostematis and Radix Isatidis; Caulis Sargentodoxae and Radix Cyathulae, Caulis Sinomenii
Rhizoma Bolbostematis claims Bulbus Fritillariae Thunbergii again, the nature and flavor bitter cold, and heat-clearing and toxic substances removing, mass dissipating and swelling eliminating especially to rheumatoid arthritis arthroncus person, can play the reducing swelling and alleviating pain effect.
The Radix Isatidis bitter cold, heat-clearing and toxic substances removing, the removing heat from blood sore-throat relieving, the merit of getting its detoxifcation is intended to help principal agent and separates external poison heresy.
The two compatibility, real committee holds up principal agent to strengthen the inside and outside pyretic toxicity of removing summer-heat, the swelling and ache of dissipation joint.
Right cold and cool medicine has ice Fu Zhixing after all, says as Zhou Xuehai: " beginning does not have ice Fu Zhiyu for the calentura medicine of a cold nature, the product that need assistant to invigorate blood circulation.After covering big calentura in all Great Cold, must have among the venation to push away the blood stasis that swings not to the utmost, if do not drive away, new life's blood can not circulate, and vigour can not be answered eventually, very has to transfer the damage person of battalion to." compatibility activating blood and removing stasis drug Caulis Sargentodoxae and Radix Cyathulae pungent in flavor and cool in property in the side, go into blood system, removing heat from blood heat, dissipating blood stasis blood, qualcomm meridian is got it in the heat and toxic materials clearing away medicine compatibility and is attacked envenoemation heat in order to dissipation poison, more helps anti-cold and cool fraud.Four medicine compatibilities are ministerial drug.
Caulis Sinomenii, nature and flavor hardship, suffering, flat.Dispelling wind and removing obstruction in the collateral, inducing diuresis and reducing edema.
Flos Lonicerae and Caulis Sinomenii compatibility, Flos Lonicerae are with dispelling wind-heat, and removing summer-heat blood poison is main, and the effect of Flos Lonicerae heat-clearing and toxic substances removing is better than Caulis Lonicerae, and the pyretic toxicity of specially clear meridians, internal organs, limbs is so be used for that the numbness that all pyretic arthralgia cause is swollen, pain, scorching hot and internal organs heat in blood poison demonstrate,proves; Caulis Sinomenii is based on the heat clearing away removing obstruction in the collateral to relieve pain, and its Detoxication is inferior to Flos Lonicerae, and can be used in arthralgia pain is main disease.The two compatibility, Flos Lonicerae get Caulis Sinomenii have been strengthened stimulating the menstrual flow and has reached network, removes the effect of pyretic arthralgia pain; Caulis Sinomenii gets Flos Lonicerae and has strengthened heat-clearing and toxic substances removing, reaches the effect of wind heat thoroughly.
2.3 adjuvant drug: the Rhizoma Zingiberis and the Radix Paeoniae Alba
Radix Paeoniae Alba nature and flavor are bitter, and acid can restrain, and hardship can expel the heat-evil, the yin fluid astringing of can enriching blood, and easing the affected liver to relieve pain can be prevented with the passing of time yin-damaging and Qi consuming of pyretic toxicity, damp and hot heresy again.
The Fang Zhongyong Rhizoma Zingiberis is the product because of clearing up internal heat by using drugs of bitter in taste and cold in nature, has the heat clearing and damp drying effect, but the heat clearing away medicine is bitter cold, sweet cold product after all, and cold and cool fraud of upseting one's stomach is arranged.Easily impairment of YANG is upset one's stomach, and compatibility Rhizoma Zingiberis one can restrict the bias of cold and cool medicine, reaches the eliminating evil positive purpose of not hindering.Two can subdue the toxicity of medicine; Three can turn round and look at and protect gastric qi.
2.4 messenger drug: Radix Cyathulae
The sweet little hardship of Radix Cyathulae, flat, return the Liver and kidney warp.It reaches network except that the rheumatism effect can help Caulis Sinomenii to stimulate the menstrual flow swollen to control arthralgia pain; Its effect of invigorating blood circulation can help the detumescence of Caulis Sargentodoxae blood stasis-eliminating and stagnation-dissipating again, and it stimulates the menstrual flow, and also tool is hot descending with drawing in the effect that reaches network, and priming is descending, and the merit of conducting blood to flow downwards is messenger drug in the side.
3. Research on Process
Medicine of the present invention is the characteristics according to former prescription clinical application, and the characteristic and the pharmacological action of each effective ingredient in the side that reports in conjunction with documents and materials by analysis, experimental study and design screening, and are confirmed through pharmacodynamics and preliminary clinical research.
The contained chemical constituent of Flos Lonicerae has chlorogenic acid, isochlorogenic acid, chromocor compound, linalool and Flos Lonicerae alcohol etc., effects such as antibacterial, antiinflammatory, immunomodulating are arranged, chlorogenic acid is dissolved in hot water, be soluble in ethanol and acetone, so with the chlorogenic acid content is pointer, adopt the extraction process condition of the preferred Flos Lonicerae of orthogonal design.More excellent process conditions are Flos Lonicerae extracting in water three times (10,6,4 times of amount of water), each 0.5 hour.
Caulis Sinomenii contains multiple alkaloids such as sinomenine, sinoacutine, michelalbine, stepharine, has clear and definite antiinflammatory, analgesic activity, and humoral immunization and cellular immunization are all had the obvious suppression effect.Sinomenine is morphine class both sexes alkaloids, is dissolved in ethanol, acetone chloroform and diluted alkaline, is slightly soluble in water.Contain phytosterin compound ecdyson and various trace elements such as Herba Cyathulae Prostratae sterol, different Herba Cyathulae Prostratae sterol in the Radix Cyathulae, free plant sterol is soluble in organic solvents such as chloroform, ether, and its glycosides then can be dissolved in ethanol.Saponin component is the higher composition of content in the Rhizoma Bolbostematis, also is its main active, by Rhizoma Bolbostematis saponin first, the Rhizoma Bolbostematis saponin second and the Bulbus Fritillariae Uninbracteatae saponin third gradegrade C.The immunosuppressive action of Rhizoma Bolbostematis early has report, and SC is increased, and helps the removing of pathogenic immune complex.The Rhizoma Bolbostematis saponin is a triterpenoid compound, soluble in water and ethanol.Content with sinomenine is index, adopts the extraction process condition of the preferred Caulis Sinomenii of orthogonal design, Bulbus Fritillariae Cirrhosae.More excellent process conditions are 16 times of amounts of ethanol of 70%, extract 2 times (1.5h, 1.5h).
Contain monoterpene glycosides compounds such as peoniflorin, Radix Paeoniae Alba glycosides, peonin in the Radix Paeoniae Alba, have effects such as antiinflammatory, antibiotic, antiviral, immunomodulating, peoniflorin is its main active.Contain chemical compounds such as anthraquinone class, salidroside, Caulis Sargentodoxae glycosides in the Caulis Sargentodoxae.Contain sinigrin, indole glycoside, indirubin, cupreol, clionasterol and several amino acids in the Radix Isatidis, containing total amino acids content is 3.8%, and the Radix Isatidis decoct all has good antibacterial and antivirus action to Gram-positive and negative bacteria.More than multiple composition in water, have dissolubility preferably, be the preferred Radix Paeoniae Alba of pointer, Caulis Sargentodoxae, Radix Isatidis extraction process condition with the peoniflorin.Through the trial test Radix Paeoniae Alba extract separately content of paeoniflorin be with Caulis Sargentodoxae, Radix Isatidis carry altogether 80.35%, so three medicines close and carry, investigated liquid volume added, extraction time, three factors of extraction time, more excellent process program extracts 3 times (1.5h, 1.5h, 1.5h) for adding 16 times of amounts of water.
Rhizoma Zingiberis contains volatile oil, mainly by Jiang Xi, gingerol, zingiberone, zingiberol, Borneolum Syntheticum etc., Rhizoma Zingiberis volatile oil makes the obvious atrophy of mouse thymus childhood, the water extract of daring to say has tangible antiinflammatory action, therefore intends adopting two lifting manipulations, extracts Rhizoma Zingiberis volatile oil, keep its distillate, and adopt the beta-cyclodextrin inclusion compound Rhizoma Zingiberis volatile oil, and increase the stability of volatile oil, the extraction of Rhizoma Zingiberis, the bag and the process conditions of volatile oil are carried out preferably.The extraction process of Rhizoma Zingiberis volatile oil is soaked 1h for adding 18 times of amounts of water, extracts 4h.Bag and technology are volatile oil-beta-schardinger dextrin-(1: 8), water-beta-schardinger dextrin-(3: 1), milling time 2h.
Flos Lonicerae water extract, Caulis Sinomenii, Radix Cyathulae, Rhizoma Bolbostematis alcohol extract adopt to filter remove impurity; The Radix Paeoniae Alba, Caulis Sargentodoxae, ginger ale extract contain more water-solubility impurity, adopt the Ethanol Treatment method to make with extra care, and are that pointer is investigated concentrated solution relative density, alcohol precipitation concentration with the paeoniflorin content.The relative density of concentrated solution is bigger to the content of paeoniflorin influence of flickering after refining, the relative density 1.05～1.07 that preferred process for refining condition is a concentrated solution (60 ℃ of heat are surveyed), and it is 50% that the determining alcohol adjustment contains the alcohol amount.
The method affect of Chinese medicine extraction liquid concentrate drying is to the quality of preparation.Flos Lonicerae is easily decomposed in middle chlorogenic acid long-time heating, should adopt concentrating under reduced pressure, drying, the temperature of being heated with reduction.Caulis Sinomenii extract and Caulis Sargentodoxae extract, Flos Lonicerae extract can form precipitation in aqueous solution, concentrate, drying mix homogeneously behind the crushing screening respectively.
Chinese medical concrete powder flowability is poor, hygroscopicity is big, should add the adjuvant increase and flow, and reduces hygroscopicity, investigates micropowder silica gel, Pulvis Talci, magnesium stearate to its flowability and hygroscopic influence with size, the percentage hydroscopicity of angle of repose.The result to be adding 4% magnesium stearate, extract powder mobile best, and hydroscopicity is minimum.
4. stability study
Adopt the reserved sample observing method to carry out the test of sample preliminarily stabilised,, prove that this sample stability is good through 3 months investigation.
B. pharmacodynamics, toxicological study result and evaluation
1. pharmacodynamic study
Medicine of the present invention is the good medicine of treatment of arthritis, and clinical effectiveness is remarkable, and in order to verify clinical efficacy, the clinical experimental basis that provides to be provided, we have carried out experimental study to medicine main pharmacodynamics of the present invention, now are reported as follows.
1.1 medicine antiinflammatory action of the present invention
1.1.1 medicine Dichlorodiphenyl Acetate of the present invention causes the analgesic activity of pain mice:
Writhing method: get 50 of 18-20g mices, male and female half and half are divided into 5 groups at random, and the 1st group is the heavy dose of group of medicine of the present invention, and dosage is 7.46 crude drugs/kg (for 20 times of people's clinical dosage); The 2nd group is that dosage group dosage is 3.73g crude drug/kg (for 10 times of people's clinical dosage) in the medicine of the present invention; The 3rd group is that medicine small dose group dosage of the present invention is 1.865g crude drug/kg (for 5 times of people's clinical dosage); The 4th group of positive medicine colguhoumia root group dosage is 0.225g/kg (for 5 times of people's clinical dosage); The 5th group of blank group given the ordinary water of equal-volume (0.2ml/200g).Irritate stomach every day once, continuous irrigation stomach 7 days.Behind last administration 30min, every Mus lumbar injection 0.6% acetic acid 0.2ml/20g Mus is heavy, writes down each Mus and the time of the 1st writhing response occurs and turn round the body number of times, and organize a t-check, the results are shown in Table 1.
Table 1 medicine Dichlorodiphenyl Acetate of the present invention causes analgesic activity n=10 X ± SD of pain mice
Group dosage (g/kg) incubation period (min) is turned round the body number of times
The heavy dose of group of medicine of the present invention 7.46 7.7 ± 1.9** 15.1 ± 12.7**
Dosage group 3.73 6.3 ± 3.1 16.5 ± 12.6* in the medicine of the present invention
Medicine small dose group 1.865 6.9 ± 2.9 18.2 ± 14.7* of the present invention
Colquhounia coccinea Wall. var. mollis (Schlecht.) Prain heel piece group 0.225 6.4 ± 2.3 18.4 ± 11.1*
Blank group equal-volume water 4.7 ± 1.7 32.4 ± 13.1
Annotate with blank group and compare
*P＜0.05
*P＜0.01
The result shows, compares with the blank group, and the heavy dose of group of medicine of the present invention can be eased pain incubation period (p＜0.01) by the significant prolongation mice; What the large, medium and small dosage group of medicine of the present invention can significantly reduce mice turns round body number of times (p＜0.01, p＜0.05), illustrates that medicine of the present invention has analgesic activity preferably.
1.1.2 medicine of the present invention is to the analgesic activity of hot plate method induced mice: with the ordinary water group relatively, the heavy dose of group of medicine of the present invention can significantly improve the mice pain threshold, p＜0.05 illustrates the heavy dose of group of medicine of the present invention, and hot plate method is caused mice also significant analgesic activity.
1.1.3 medicine of the present invention is to the influence of mice auricle swelling: with ordinary water group ratio, in the medicine of the present invention, low dose of mice auricle swelling p＜0.05 that causes by dimethylbenzene of all suppressing, in its antiinflammatory action, small dose group organizes suitable with the positive.
1.14 medicine of the present invention is to the influence of mice granuloma induced by implantation of cotton pellets:
Get 50 of the male rats of body weight 150g ± 20g, be divided into 5 groups at random, 10 every group.The 1st group of heavy dose of group of medicine of the present invention, dosage are 3.73g crude drug/kg (for 10 times of people's clinical dosage); Dosage group in the 2nd group of medicine of the present invention, dosage are 1.865g crude drug/kg (for 5 times of people's clinical dosage); The 3rd group of medicine small dose group of the present invention, dosage are 0.933g crude drug/kg (for 2.5 times of people's clinical dosage); The 4th group of positive drug colguhoumia root group, dosage is 0.1125g/kg; The 5th group of blank group gives equal-volume (2ml/200g) ordinary water.Rat is used etherization, and at the left and right sides of each Mus groin iodine disinfection, after 75% ethanol took off iodine, each cut the osculum of 1cm length.The sterilization cotton balls (adding gentamycin liquid 0.1ml and oven dry) that will be weighed as 20mg with tweezers is subcutaneous from the osculum implantation, skin suture wrapping immediately.Began gastric infusion, successive administration 6 days the same day from performing the operation.Rat was weighed in the 7th day, open former otch, cotton balls is taken out together with connective tissue on every side, reject fatty tissue, put in the baking oven 60 ℃ of oven dry and weigh.With claim weight deduct the former weight of cotton balls and promptly get granulomatous weight.Organize a t check.The results are shown in Table 2.
Table 2 medicine of the present invention is to the bullate n=8 X ± SD that influences of rat granuloma
Group dosage (g/kg) granulation dry weight (mg/100g body weight)
The heavy dose of group of medicine of the present invention 3.73 26.8 ± 3.1**
Dosage group 1.865 27.3 ± 2.8** in the medicine of the present invention
Medicine small dose group 0.933 29.1 ± 2.2* of the present invention
Colguhoumia root group 0.225 28.8 ± 3.6*
Model group equal-volume water 33.1 ± 3.7
Annotate with model group and compare
*P＜0.05
*P＜0.01
The result shows, compares with model group, and the large, medium and small dosage group of medicine of the present invention has remarkable inhibitory action (p＜0.01, p＜0.05) to rat granuloma is swollen, illustrates that medicine of the present invention has antiinflammatory action preferably to chronic inflammatory disease.
1.2 medicine of the present invention is to the effect of rat paw edema
1.2.1 medicine of the present invention is to the effect of rat carrageenan foot swelling: with the ordinary water group relatively, the big or middle dosage group of medicine of the present invention gives carrageenin 6h, 8h rat has remarkable effect (p＜0.01 to its foot swelling, p＜0.05), illustrates that medicine of the present invention has antiinflammatory action preferably to chronic inflammatory disease.
1.2.2 medicine of the present invention is to the therapeutical effect of rat anti adjuvant arthritis:
Get 48 of the healthy male rats of body weight 150-200g, measure the left and right metapedes sole of the foot of every Mus girth with tape, injection Freund ' s Freund's complete adjuvant 0.05ml causes inflammation in the left back sufficient sole of the foot of every then Mus.After causing scorching 19 days, measure each Mus foot sole of the foot girth, calculate the swollen degree of foot, rat is divided into 6 groups at random by the swollen degree of foot, beginning administration, grouping and the same 2.3.1 of dosage.Be administered once every day, 2 weeks of continuous irrigation stomach.In the forward and backward left and right hind foot swelling of the rat degree of measuring every a day of administration, observe body weight change, and the incidence rate and the severity of forelimb, ear and afterbody pathological changes, nodular situation takes place carry out following classification according to forelimb swelling degree gill, tail: it is 0 grade (0 minute) that forelimb does not have obvious swelling, the visible swelling of forelimb is I level (1 minute), the obvious swelling of forelimb is II level (2 minutes), the obvious swelling of forelimb and diabrosis is arranged is III level (3 minutes), and ear, tail is swollen or nodosity is IV level (4 minutes).
The scorching front foot sole of the foot girth of the scorching metapedes sole of the foot girth of swelling degree=cause-cause
With model group relatively, the heavy dose of group of medicine of the present invention promptly begins to occur remarkable inhibitory action (p＜0.01, p＜0.05) administration the 7th day to its foot swelling; Middle dosage group began to occur remarkable inhibitory action on the 9th day in administration, and small dose group remarkable inhibitory action occurred in the time of the 11st day.Illustrate that swelling has therapeutical effect preferably to medicine of the present invention to the adjuvant arthritis constitutional.
With model group relatively, the heavy dose of group of medicine of the present invention promptly begins to occur remarkable inhibitory action (p＜0.05) administration the 7th day to its foot swelling; In, small dose group began to occur remarkable inhibitory action on the 9th day in administration.Illustrate that medicine of the present invention also has therapeutical effect preferably to the Secondary cases swelling of adjuvant arthritis offside limb.
Compare with model group, swelling has remarkable inhibitory action to the heavy dose of group of medicine of the present invention to forelimb.The results are shown in Table 3
Table 3 medicine of the present invention is to the therapeutical effect n=8 X ± SD of rat assist agent arthritis forelimb swelling
Group dosage (g/kg) forelimb or ear (tail) pathological changes integration
The heavy dose of group 3.73 0.50 ± 0.76 of medicine of the present invention
The dosage group 1.865 0.63 ± 0.92 in the medicine of the present invention
Medicine small dose group 0.933 0.88 ± 1.13 of the present invention
Colguhoumia root group 0.1125 1.13 ± 1.13
Ibuprofen group 0.02 0.38 ± 0.52*
Model group equal-volume 1.88 ± 1.46
Annotate with model group and compare
*P＜0.05
*P＜0.01
1.2.3 medicine of the present invention is to the preventive effect of rat anti adjuvant arthritis: with the ordinary water group relatively, the heavy dose of group of medicine of the present invention promptly begins to occur in the remarkable inhibitory action (p＜0.01, p＜0.05) the dosage group and remarkable inhibitory action is arranged causing scorching back in the time of the 17th day causing scorching back the 11st day to its foot swelling.Illustrate that the big or middle dosage of medicine of the present invention has preventive effect preferably to adjuvant arthritis.
1.2.4 medicine of the present invention is to the influence of mice capillary permeability: with the ordinary water group relatively, medicine of the present invention is big or middle, the dosage group can significantly suppress the mice capillary permeability.
1.3 medicine of the present invention is to mouse immune organ weight's influence: the large, medium and small dosage of medicine of the present invention be I believe thymus and spleen weight zero difference with positive group and ordinary water group.
1.4 medicine of the present invention is to the influence of rat abdominal cavity leukoplania: in the medicine of the present invention, low dose of and ordinary water group compares the rat leukocyte migration that remarkable inhibitory action (p＜0.05) is arranged.
1.5 medicine of the present invention is to the granulomatous influence of rat Oleum Tiglii air bag: with the ordinary water group relatively, the large, medium and small dosage of medicine of the present invention has extremely significantly inhibitory action to rat Oleum Tiglii air bag granuloma.Illustrate that medicine of the present invention has antiinflammatory action preferably.
1.6 medicine immunization test of the present invention
1.6.1 medicine of the present invention is to mouse immune organ weight's influence: the large, medium and small dosage group of medicine of the present invention and positive drug group and ordinary water group ratio, thymus and spleen weight zero difference.
1.7 medicine of the present invention is to the influence of mice DCHR: with ordinary water group ratio, in the medicine of the present invention, small dose group all can extremely significantly suppress by the caused Mice Auricle edema of dinitrochlorobenzene sensitization (p＜0.01), its anti-allergy action is very remarkable.
1.8 conclusion
Pharmacological experiment shows that medicine of the present invention has obvious anti-inflammatory and analgesic effect; Adjuvant-induced arthritis there are significant treatment and preventive effect; Immunization is preferably arranged, the mice delayed allergy is had stronger inhibitory action.More than effect is the pharmacological basis of its performance clinical efficacy.
2. toxicological study
2.1 acute toxicity test
With Kunming mouse, half and half 30 of male and female, fasting 24 hours, can't help water, drug suspension of the present invention is given in gastric lavage, is administered three times in 1st, a 0.4ml, the administration total amount was 1.2ml on 1st, was equivalent to the 4.49g crude drug, observed seven days behind the medicine, drug toxicity of the present invention is little, can not survey LD50, so, can only adopt oral administration, give its Cmax, heap(ed) capacity, obtain the mouse tolerance dose multiple.The dosis tolerata multiple of medicine mice of the present invention is 605.4 times, substantially exceeded the requirement of 100 times of trial drugs, the mice diet movable normal, hair color is smooth, the acute toxic reaction of not finding mice.
2.2 long term toxicity test
2.2.1 laboratory animal: wistar kind rat, Mus age was 8 weeks, male and female half and half, body weight 180g ± 20g, is provided the animal quality certification numbers 200001003 by 160 by Shandong Province's Experimental Animal Center.
Experimental drug: medicine of the present invention, by Shandong Traditional Chinese Medicine University's self-control, No. 0 capsule of lot number, (containing crude drug 22.47g/ day).The crude drug amount contained according to large, medium and small dosage is made into suspension with capsule 's content in warm water.
2.2.2 method:
After rat fed for 1 week, evenly be divided into 4 groups, wherein give the large, medium and small maximum dose of medicine of the present invention for 1,2,3 group, the 4th group is the blank group, gives isopyknic ordinary water.
Dosage: people clinical every day of dosage 22.47g crude drug/people/day, the people calculates 22.47g/60kg by the 60kg body weight and is: 0.37g crude drug/kg; Rat is pressed the 200g body weight and calculates, and is: 0.074g crude drug/200g rat, and individual dosage group is respectively:
Heavy dose of group is 0.047g * 50g=3.7g crude drug/200g rat, that is: 18.5g crude drug/kg is equivalent to 50 times of the clinical consumption of people.
Middle dosage group is with one times of above medicinal liquid dilution, and dosage is 9.25g crude drug/kg, is equivalent to 25 times of the clinical consumption of people.
Small dose group is with 10 times of above medicinal liquid dilutions, and dosage is 3.7g crude drug/kg, is equivalent to 10 times of the clinical consumption of people.
Rat observing time is 120 days, every morning gastric infusion once, irritating stomach dosage is 4ml/200g, in weighing weekly once before the administration and behind the medicine, adjusts the administration volume to ensure to dose according to body weight.Before medicine and 30 days, 60 days, 90 days, 120 days (convalescent period) of administration each group get 20 (male and female half and half) at random and get blood and survey every biochemical indicators such as routine blood test (erythrocyte, leukocyte, hemoglobin and platelet count and leukocyte differential count) and liver, renal function.Administration after 60 days every group put to death 10 rats (male and female half and half), putting to death 120 days (convalescent period) of 2/3rds animal (20 every group) after 90 days again will remain rat and all put to death, each organ of perusal internal organs have no abnormal after, getting main organs (heart, liver, spleen, lung, kidney, stomach, adrenal gland, thyroid, thymus, uterus, ovary, testis, prostate) weighs respectively, calculate each organ coefficient, get the same area of each internal organs and do the pathology section with 10% formaldehyde fixed.
Each internal organs of each dosage group are all no abnormal as a result.Whole experiment totally 120 days, rat perusal diet, behavior, activity, body surface etc. are all no abnormal.Check respectively that below data are all in normal range.So show that medicine life-time service of the present invention is safe.
C. clinical effectiveness
1. purpose: the objective of the invention is to develop a kind of treatment rheumatoid arthritis, the III kind new medicine that belongs to the card of damp and hot resistance network, this medicine is mainly used in rheumatoid arthritis in active stage, and ankylosing spondylitis, osteoarthritis, arthritic psoriasis, Behcet disease are main clinical manifestation person with the red and swollen heat pain in joint.
2. the prescription source is with definite
Medicine of the present invention is made up of medicines such as Flos Lonicerae, Caulis Sinomenii, the Radix Paeoniae Alba, Rhizoma Bolbostematis, Caulis Sargentodoxae, Radix Isatidis, Rhizoma Zingiberis, Radix Cyathulaes, its effect is heat-clearing and toxic substances removing, expelling wind and removing dampness, promoting blood circulation and stopping pain, be used for the treatment of rheumatoid arthritis patients, belong to categories such as tcm internal medicine " pyretic arthralgia ", " severe and migratory arthralgia ".Medicine of the present invention is that national distinguished veteran doctors of TCM, rheumatism immunological diseases expert, the long-term drug test of the tcm internal medicine Zhang Minghe of Shandong Traditional Chinese Medicine University, Song Shaoliang professor warp and clinical trial are made.
3.I clinical trial phase
Calendar year 2001,120 routine rheumatoid arthritis active stage patients are treated, wherein test group 84 examples are taken medicine of the present invention, and each 4, every day 3 times, 6 weeks were 1 course of treatment; Matched group 58 examples are taken YISHEN JUANBI WAN, each 8 grams, and every day 2 times, the course of treatment is the same.Efficacy assessment standard (formulating according to the sick clinical guidance principle of treatment by Chinese herbs numbness) medicine of the present invention shows control rate 59.52% to 84 example active stage therapeutic outcome total effective rates 94.25%, and matched group total effective rate 82.76% shows control rate 37.93%.The cardinal symptom of treatment group simultaneously and matched group, sign efficacy analysis, and ESR, PGE
2The contrast difference has remarkable meaning.In Chinese medical discrimination typing opinion was controlled, medicine of the present invention was evident in efficacy to rheumatoid arthritis damp and hot resistance network of active stage disease.
Therapeutic outcome shows that also medicine of the present invention has no side effect to internal organs such as Liver and kidney, by inspections such as the patient's liver function before and after the treatment, kidney merit, routine blood test are found no abnormal change.
In sum, it is remarkable that Drug therapy rheumatoid arthritis of the present invention has therapeutic effect, has no side effect, cheap, taking convenience, the advantage that does not recur after the treatment.
(4) specific embodiment
Embodiment 1
Accurately take by weighing the raw material of following weight: Flos Lonicerae 360g, Caulis Sinomenii 285g, Radix Paeoniae Alba 250g, Rhizoma Bolbostematis 178g, Rhizoma Zingiberis 54g, Caulis Sargentodoxae 250g, Radix Isatidis 250g, Radix Cyathulae 250g.
Flos Lonicerae, Radix Cyathulae extracting in water three times (8,6,4 times of amount of water), each 1 hour, merge the water extract, filter, concentrating under reduced pressure, drying were pulverized 40 mesh sieves.
Caulis Sinomenii, Rhizoma Bolbostematis are merged, add 16 times of amounts of ethanol of 70%, extract 2 times (1.5h, 1.5h), merge alcohol extract, decompression recycling ethanol also is concentrated into normal concentration, and drying under reduced pressure was pulverized 40 mesh sieves.
The Radix Paeoniae Alba, Caulis Sargentodoxae, Radix Isatidis are merged, add 16 times of amounts of water, extract 3 times (1.5h, 1.5h, 1.5h), merge the water extract, filter, be evaporated to relative density 1.05 (60 ℃ of heat are surveyed), adding ethanol to determining alcohol is 50%, leaves standstill cold preservation, filter, decompression filtrate recycling ethanol also is concentrated into normal concentration, and drying under reduced pressure was pulverized 40 mesh sieves.
Get Rhizoma Zingiberis and add 18 times of amounts of water, soak 1h, extract 4h, volatile oil device is in addition collected, and herbal extracts such as the aqueous extract and the Radix Paeoniae Alba merge; Volatile oil cyclodextrin inclusion compound, clathrate process are volatile oil-beta-schardinger dextrin-(1: 8), water-beta-schardinger dextrin-(3: 1), and milling time 2h, the clathrate crushed after being dried becomes fine powder.
With above-mentioned dry extract and cyclodextrin clathrate mix homogeneously, add 2% magnesium stearate, after the mixing, incapsulate, make 1000, the 0.53g/ grain.
Usage and consumption: oral, three times on the one, 4/time.
Embodiment 2
Accurately take by weighing the raw material of following weight: Flos Lonicerae 380g, Caulis Sinomenii 230g, Radix Paeoniae Alba 300g, Rhizoma Bolbostematis 160g, Rhizoma Zingiberis 80g, Caulis Sargentodoxae 220g, Radix Isatidis 280g, Radix Cyathulae 250g.
With above-mentioned dry extract and cyclodextrin clathrate mix homogeneously, add 2% magnesium stearate, after the mixing, incapsulate, make 1000, the 0.55g/ grain.
Usage and consumption: oral, three times on the one, 4/time.
Embodiment 3
Accurately take by weighing the raw material of following weight: Flos Lonicerae 310g, Caulis Sinomenii 280g, Radix Paeoniae Alba 200g, Rhizoma Bolbostematis 200g, Rhizoma Zingiberis 35g, Caulis Sargentodoxae 290g, Radix Isatidis 220g, Radix Cyathulae 290g.
Preparation method is identical with embodiment 1.Get extract 480g.Add an amount of microcrystalline Cellulose, tabletting.0.5g/ sheet.
Usage and consumption: oral, three times on the one, 4 slices/time.
Claims (5)
1. Chinese medicine composition for the treatment of rheumatoid arthritis is characterized in that: be to make by following materials of weight proportions and pharmaceutically acceptable auxiliaries,
Flos Lonicerae 300-400g Caulis Sinomenii 230-300g Radix Paeoniae Alba 200-300g
Rhizoma Bolbostematis 150-200g Rhizoma Zingiberis 30-80g Caulis Sargentodoxae 200-300g
Radix Isatidis 200-300g Radix Cyathulae 200-300g
2. Chinese medicine composition according to claim 1 is characterized in that: above-mentioned materials of weight proportions is,
Flos Lonicerae 340-380g Caulis Sinomenii 260-300g Radix Paeoniae Alba 220-280g
Rhizoma Bolbostematis 160-200g Rhizoma Zingiberis 40-70g Caulis Sargentodoxae 220-280g
Radix Isatidis 220-280g Radix Cyathulae 220-280g
3. Chinese medicine composition according to claim 1 is characterized in that: above-mentioned materials of weight proportions is,
Flos Lonicerae 360g Caulis Sinomenii 285g Radix Paeoniae Alba 250g
Rhizoma Bolbostematis 178g Rhizoma Zingiberis 54g Caulis Sargentodoxae 250g
Radix Isatidis 250g Radix Cyathulae 250g
4. according to claim 1,2 or 3 described Chinese medicine compositions, it is characterized in that: described Chinese medicine composition is a capsule formulation.
5. according to claim 1,2 or 3 described Chinese medicine compositions, it is characterized in that: described Chinese medicine composition is tablet and other dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101146426A CN100425280C (en) | 2003-12-25 | 2003-12-25 | Chinese medicinal composition for treating rheumatoid arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101146426A CN100425280C (en) | 2003-12-25 | 2003-12-25 | Chinese medicinal composition for treating rheumatoid arthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1554395A true CN1554395A (en) | 2004-12-15 |
| CN100425280C CN100425280C (en) | 2008-10-15 |
Family
ID=34337179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2003101146426A Expired - Fee Related CN100425280C (en) | 2003-12-25 | 2003-12-25 | Chinese medicinal composition for treating rheumatoid arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100425280C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102755617A (en) * | 2012-08-02 | 2012-10-31 | 李雪英 | External medicinal liquor for use in ear point channels-collaterals therapy |
| CN104435893A (en) * | 2014-12-11 | 2015-03-25 | 赵玉 | Gout-resisting, inflammation-resisting, blood circulation-promoting and blood stasis-removing and pain-alleviating traditional Chinese medicine composition |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1148210C (en) * | 2001-01-12 | 2004-05-05 | 米绍武 | Exterior-applied Chinese-medicinal plaster for treating bone tuberculosis and its preparing process |
-
2003
- 2003-12-25 CN CNB2003101146426A patent/CN100425280C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102755617A (en) * | 2012-08-02 | 2012-10-31 | 李雪英 | External medicinal liquor for use in ear point channels-collaterals therapy |
| CN102755617B (en) * | 2012-08-02 | 2013-10-16 | 李雪英 | External medicinal liquor for use in ear point channels-collaterals therapy |
| CN104435893A (en) * | 2014-12-11 | 2015-03-25 | 赵玉 | Gout-resisting, inflammation-resisting, blood circulation-promoting and blood stasis-removing and pain-alleviating traditional Chinese medicine composition |
| CN104435893B (en) * | 2014-12-11 | 2017-07-25 | 赵玉 | Antigout, anti-inflammatory, promoting blood circulation and removing blood stasis, analgesic Chinese medicine composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100425280C (en) | 2008-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1316990C (en) | Chinese medicinal composition, preparation method and quality control method thereof | |
| CN1058620C (en) | Yingfengaidi medicine and its production process | |
| CN1197614C (en) | Chinese medicine cap sule for treating prostatic disorders | |
| CN1554395A (en) | Chinese medicinal composition for treating rheumatoid arthritis | |
| CN1966001A (en) | Medicament for treating inflammation and preparation method thereof | |
| CN1308019C (en) | Chinese medicinal composition for treating chronic pelvic inflammation and preparation method thereof | |
| CN1233364C (en) | Chinese medicine for treating digestive ulcerating sore and its preparation method | |
| CN105770691A (en) | Medicinal preparation for treating cervical cancer and application thereof | |
| CN1958028A (en) | Preparation of Chinese traditional medicine for treating hyperplasia of prostate | |
| CN1541691A (en) | Acute icterohepatitis treating Chinese traditional medicine and its preparation | |
| CN1823980A (en) | Chinese medicinal preparation for treating chronic prostatitis and its manufacturing method | |
| CN1686272A (en) | Medicine for treating chronic prostatitis and its preparation method | |
| CN1186052C (en) | Medicine for treatment of pelvic inflammation, its preparation and preparing method | |
| WO2004084924A1 (en) | Pharmaceutical composition for treatment of bph and preparation thereof | |
| CN1475261A (en) | Medicine for treating gastral cavity pain and its preparation method | |
| CN101053624A (en) | Traditional Chinese medicinal for treating prostatic hyperplasia and chronic prostatitis and its preparation process | |
| CN1733197A (en) | Medicine for curing chronic prostatitis and process for preparing the same | |
| CN1308031C (en) | Chinese medicine composition for treating biliary tract disease, preparing method and use | |
| CN1304032C (en) | Prostate proliferation treating medicine composition | |
| CN100350953C (en) | Pharmaceutical composition for treating virus infectious high fever and preparation method thereof | |
| CN1250237C (en) | Medicine combination containing white atractylodes rhizome and its preparation method | |
| CN1966047A (en) | Chinese medicinal formulation for treating prostate hyperplasia | |
| CN1265810C (en) | A pharmaceutical composition for treating cyclomastopathy, and its preparation method | |
| CN1679908A (en) | Chinese medicine for treating tumor and preparation thereof | |
| CN1569085A (en) | Pharmaceutical composition for treating rheumatic arthritis and rheumatoid arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081015 Termination date: 20100125 |